KR20180002079A - Composition containing ginseng berry extract using processing of herbal medicine - Google Patents
Composition containing ginseng berry extract using processing of herbal medicine Download PDFInfo
- Publication number
- KR20180002079A KR20180002079A KR1020170176447A KR20170176447A KR20180002079A KR 20180002079 A KR20180002079 A KR 20180002079A KR 1020170176447 A KR1020170176447 A KR 1020170176447A KR 20170176447 A KR20170176447 A KR 20170176447A KR 20180002079 A KR20180002079 A KR 20180002079A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- ginseng fruit
- skin
- extract
- cosmetic composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 81
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 79
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 79
- 239000000284 extract Substances 0.000 title claims abstract description 55
- 241000208340 Araliaceae Species 0.000 title claims abstract 15
- 238000012545 processing Methods 0.000 title abstract description 7
- 235000021028 berry Nutrition 0.000 title abstract description 5
- 241000411851 herbal medicine Species 0.000 title description 2
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 61
- 239000002537 cosmetic Substances 0.000 claims description 25
- 239000006210 lotion Substances 0.000 claims description 21
- 230000002087 whitening effect Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 9
- 239000004459 forage Substances 0.000 claims description 9
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 239000006260 foam Substances 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000004902 Softening Agent Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- -1 pack Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000009759 skin aging Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 241000209140 Triticum Species 0.000 claims 1
- 235000021307 Triticum Nutrition 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 235000013312 flour Nutrition 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 6
- 229940124595 oriental medicine Drugs 0.000 abstract 1
- 238000003672 processing method Methods 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 description 66
- 210000003491 skin Anatomy 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 238000009472 formulation Methods 0.000 description 33
- 230000000694 effects Effects 0.000 description 28
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 102000029816 Collagenase Human genes 0.000 description 12
- 108060005980 Collagenase Proteins 0.000 description 12
- 229960002424 collagenase Drugs 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 10
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 10
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 102000016387 Pancreatic elastase Human genes 0.000 description 9
- 108010067372 Pancreatic elastase Proteins 0.000 description 9
- 210000002510 keratinocyte Anatomy 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000037394 skin elasticity Effects 0.000 description 8
- 244000273928 Zingiber officinale Species 0.000 description 7
- 235000006886 Zingiber officinale Nutrition 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000004744 fabric Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 235000008397 ginger Nutrition 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 5
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 229960001295 tocopherol Drugs 0.000 description 5
- 229930003799 tocopherol Natural products 0.000 description 5
- 235000010384 tocopherol Nutrition 0.000 description 5
- 239000011732 tocopherol Substances 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229940107131 ginseng root Drugs 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012930 cell culture fluid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000036572 transepidermal water loss Effects 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- AWFYPPSBLUWMFQ-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=C2 AWFYPPSBLUWMFQ-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- DDKGKOOLFLYZDL-UHFFFAOYSA-N 3',4',7-trihydroxyisoflavone Chemical compound C=1C(O)=CC=C(C2=O)C=1OC=C2C1=CC=C(O)C(O)=C1 DDKGKOOLFLYZDL-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000013569 fruit product Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101150014691 PPARA gene Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229910052620 chrysotile Inorganic materials 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008341 cosmetic lotion Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- CWBIFDGMOSWLRQ-UHFFFAOYSA-N trimagnesium;hydroxy(trioxido)silane;hydrate Chemical compound O.[Mg+2].[Mg+2].[Mg+2].O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-] CWBIFDGMOSWLRQ-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 한방 가공 기술인 포제를 활용하여 가공된 인삼 열매 추출물을 함유하는 조성물에 관한 것으로서, 보다 상세하게는 인삼의 지상부 중에서 독특한 성분과 조성을 갖는 인삼 열매를 포제를 이용하여 가공된 인삼 열매 추출물을 함유함으로써 미백, 항노화, 보습 등의 효능을 제공할 수 있는 조성물에 관한 것이다.The present invention relates to a composition containing a processed ginseng fruit extract using a forage processing technology, and more particularly, to a composition containing a ginseng fruit extract having a unique composition and composition among the above-mentioned ginseng, Thereby providing an effect of whitening, anti-aging, moisturizing and the like.
포제(匍制)는 한방이론에 근거하여 약재를 가공처리 함으로써 약재 본래의 성질을 변화시키는 제약기술(製藥技術)이다. 어떤 약재는 독성이 있거나 성질이 매우 강하여 직접 복용할 수 없고 어떤 약재는 쉽게 약성이 변해 오래 저장 할 수 없으며 또 어떤 것은 잡질과 어느 부분을 제거하여야 사용할 수 있는 것이 있다. 또한 동일한 약재라고 하여도 생재와 숙재는 성질이 같지 않거나 작용에서 차이가 나는 경우가 있다. 이런 약재를 사용하기에 앞서 반드시 가공을 하여야 하는데 이를 약용식물의 포제(匍制)라 한다. Foje (匍 制) is a pharmaceutical technology (pharmaceutical technology) that changes the original properties of medicines by processing the medicines based on the oriental theory. Some medicines are toxic or very strong in nature and can not be taken directly. Some medicines can not easily be stored for a long time and others can be used only after removing some parts and parts. Also, even if the same medicines are used, there is a case where the properties of the raw material and the raw material are not same or different from each other. Before using this medicinal product, it must be processed, which is called a medicinal plant.
포제는 경우에 따라서 보료(輔料)를 가하여 함께 가공하는데, 보료를 사용하는 것은 변증에 따라 용약의 목적을 달성하기 위함이다. 약물의 포제에 사용하는 보료의 종류가 다양하기 때문에 각기 다른 성질과 작용이 있으며, 이로 인해 포제한 약재가 일으키는 작용도 각기 다르다. 상용되는 보료의 종류는 무수히 많으나, 일반적으로는 크게 액체 보료와 고체 보료로 분류할 수 있다. 액체 보료로는 술, 식초, 꿀, 생강즙, 감초즙, 흑두즙, 식염수, 미감수, 젖, 동변(7세 미만 아이의 소변), 석회수 등을 사용하며, 고체 보료로는 쌀, 밀기울, 백반, 두부, 흙, 합분, 모래 등을 사용한다. Foams are sometimes processed together by adding a supplement, and the use of the supplement is to achieve the purpose of the drug according to the dialect. Because of the variety of types of pills used in drug formulations, they have different properties and actions, and the resulting action of the medicinal formulations is different. There are a myriad of commonly used types of supplements, but generally they can be broadly categorized as liquid supplements and solid supplements. Liquid ingredients include alcohol, vinegar, honey, ginger juice, licorice juice, black bean juice, saline, unmeaned water, milk, urine (urine of children under the age of 7) and lime water. Solid foods include rice, bran, Tofu, earth, ply, sand, etc. are used.
한약재를 포제하는 목적은 ① 약물을 청결하게 하고, 저장에 용이하게 하며, ② 약물의 독성과 부작용을 저하시키거나 제거하고, ③ 약성을 변화시켜 약을 더욱 효과적으로 만드며, ④ 약물의 치료 효과를 증강시키고, ⑤ 약재의 나쁜 냄새와 맛을 없애 복용하기 좋게 하기 위함이다.The purpose of purifying herbal medicine is to ① clean the drug and make it easy to store ② reduce or eliminate the toxicity and side effects of the drug ③ change the drug to make the drug more effective ④ improve the therapeutic effect of the drug And (5) to remove the bad smell and taste of the medicinal materials so as to make them good for taking.
한편, 피부는 신체 표면을 완전히 덮고 있는 가장 큰 기관으로, 외부로부터 신체를 보호하는 최외곽 방어막을 형성하고 있다. 나이가 증가함에 따라 다른 신체 기관과 마찬가지로 노화가 진행되는데, 피부의 경우 미적 판단의 기준이 되는 경우가 많아 최근 피부 노화의 예방 및 억제에 관심이 모아지고 있다. On the other hand, the skin is the largest organ completely covering the surface of the body, and forms the outermost protective film for protecting the body from the outside. As the age increases, aging progresses like other body organs. Skin is often a criterion for aesthetic judgment, and attention is now focused on prevention and inhibition of skin aging.
진피의 구조를 살펴보면, 교원섬유(콜라겐, collagen)가 입체구조를 이루고 그 사이에 신축성이 강한 탄력섬유(elastin)가 스프링처럼 작용하여 피부의 탄력을 유지해 준다. 나이가 들어감에 따라 진피 중의 교원섬유가 파괴되고 탄력섬유도 체내에서 생성되는 말론 디알데히드(MDA)에 의해 분자 사슬 사이의 가교 결합이 형성되어 신축성이 떨어지게 된다. 노화가 진행되면 피부 구조를 유지하는 섬유 외에 세포외 공간을 채우고 있는 물질들의 체내 생성량도 줄어들게 된다. 건강한 피부의 각질층은 15~20%의 수분을 함유하고 있으며 수분이 10% 이하로 떨어지면 피부가 건조해지고 윤기와 탄력이 없어져 주름이 증가하게 된다. 이 모든 결과로 인해 노화된 피부는 탄력을 잃고 주름이 발생하게 된다. Looking at the structure of the dermis, the collagen fibers (collagen) form a three-dimensional structure, elastic fibers between them (elastin) acts like a spring to maintain the elasticity of the skin. As age grows, collagen fibers in the dermis are destroyed and elastic fibers are formed in the body by malondialdehyde (MDA) to form crosslinks between molecular chains, resulting in poor elasticity. As the aging progresses, the amount of the substances that fill the extracellular space as well as the fiber that maintains the skin structure is reduced. The healthy stratum corneum contains 15 ~ 20% of water, and when the moisture falls below 10%, the skin becomes dry, the gloss and elasticity disappear, and the wrinkles increase. All of these results cause the aged skin to lose elasticity and wrinkle.
또한, 피부에 대하여 관심이 집중되는 다른 부분은 피부색과 관련된 것으로서, 피부색 결정 요인 중에서 가장 큰 부분을 차지하는 것이 피부 중 멜라닌의 분포상태 및 양이다. 멜라닌(melanin)은 멜라노사이트(melanocyte)에서 생성이 되는데 이 멜라노사이트에는 티로시나제 등의 효소가 존재하며, 이들이 함께 작용하여, 생체내에 항상 존재하는 티로신(tyrosine)이라는 아미노산을 기질로 중합화 산화반응을 함으로 흑갈색의 색소인 멜라닌을 형성 하게 된다. 이렇게 형성된 멜라닌은 멜라노사이트의 수지상 돌기를 통하여 케라티노사이트(keratinocyte)라는 표피 세포로 이동한다. 여기서 멜라닌은 핵주변에 모자와 같은 구조를 형성하여 자외선으로부터 유전자를 보호하고 자유 라디칼(free radical)을 제거하여 세포 내 단백질을 보호하는 등 중요한 역할을 하게 된다. 생체 내에는 멜라닌을 분해하는 효소가 없고 다만 케라티노사이트가 표피에서 떨어져나갈 때 같이 피부에서 떨어져나가는 것으로 제거된다. 하지만 멜라닌이 필요 이상으로 많이 생기게 되면 기미나 주근깨, 점 등과 같은 과색소침착증을 유발하여 미용상으로 좋지 않은 결과를 가져오게 된다. 멜라닌 생성에 영향을 미치는 인자는 여러 가지가 알려져 있는데, 자외선에 의하여 일어나는 멜라닌 생산의 항진 그리고 이에 따른 색소 침착이 화장품 분야에서 아주 중요하다. 색소 침착 예방목적으로 미백화장품에 배합되는 약제의 기본적인 메커니즘은 티로시나아제(tyrosinase) 작용 억제, 티로시나아제 생성 억제, 멜라닌 생성 미디에이터의 억제, 기존 멜라닌의 환원 및 광산화 억제, 멜라닌 배설의 촉진, 및 자외선 커트 등이다. In addition, the other part where attention is focused on the skin is related to the skin color, and the distribution and the amount of melanin in the skin occupy the largest portion among the determinants of the skin color. Melanin is produced in melanocytes. These melanocytes contain enzymes such as tyrosinase. They work together to form an enzyme called tyrosine, which is always present in the body. Thereby forming a dark brown pigment melanin. The melanin thus formed migrates to the epidermal cell called keratinocyte through the dendrites of melanocytes. Here, melanin forms a hat-like structure around the nucleus, which protects genes from ultraviolet rays and eliminates free radicals, thereby protecting the intracellular proteins. In vivo, there is no enzyme that breaks down melanin, but it is removed as the keratinocyte falls away from the skin when it falls off the epidermis. However, when melanin is produced more than necessary, it induces hypercholesterolemia such as spots, freckles, and dots, resulting in poor cosmetic results. There are various factors that affect the production of melanin. The increase of melanin production caused by ultraviolet rays and the pigmentation thereof are very important in the cosmetics field. The basic mechanisms of pharmaceuticals incorporated into whitening cosmetics for the prevention of pigmentation are inhibition of tyrosinase action, inhibition of tyrosinase production, inhibition of melanin-producing mediators, reduction of existing melanin and inhibition of photo-oxidation, promotion of melanin excretion, and And ultraviolet rays cut.
자외선 노출 환경속에서도 하얀 피부를 갖고자 하는 여성들의 욕구에 따라서 피부 색소 이상 증상과 과색소 침착 등의 예방과 개선에 대한 수요가 더욱 늘어 나고 있으며 이에 과도한 멜라닌 생성을 막는 미백제품 개발이 필요하게 되었고 그 동안 많은 노력들이 이루어졌다. 그 구체적인 예를 들면, 코지산(kojic acid), 알부틴(arbutin) 등과 같은 티로시나제 활성을 저해하는 억제제들, 하이드로퀴논(hydroquinone), 비타민 A, 비타민 C 및 이들의 유도체 등이 있다. 그러나, 이들은 피부에 대한 안전성, 제형 내에서의 안정성 및 미백효과의 불충분으로 인해 그 사용이 제한되고 있다. According to the desire of women who want to have white skin even in the ultraviolet exposure environment, the demand for prevention and improvement of skin pigmentation abnormality and hyperpigmentation is increasing more and it is necessary to develop a whitening product which prevents excessive melanin production, Many efforts have been made during this period. Specific examples thereof include inhibitors which inhibit tyrosinase activity such as kojic acid and arbutin, hydroquinone, vitamin A, vitamin C and derivatives thereof. However, they are limited in their use due to safety to the skin, stability in the formulation and insufficient whitening effect.
최근 화장품 분야에서는 천연물의 사용이 두드러지고 있으며, 보습력과 노화 개선 기능, 항산화 효과가 우수하고, 특히 피부 노화 개선 효과 면에서 우수하다고 보고된 천연물 추출물을 이용한 화장료 조성물에 대해서도 많은 연구가 이루어지고 있다. 그러나, 통상의 방법으로 추출한 천연물 추출물을 사용하는 조성물들은 원하는 미백, 주름 개선, 항산화 등의 효과가 미미할 뿐 아니라, 이러한 추출물의 활성을 지속적으로 유지, 제어하기가 어려워 실용성이 높지 않았다.In recent years, much research has been conducted on cosmetic compositions using natural extracts, which are reported to have remarkable use of natural products in recent years, excellent moisturizing ability, aging-improving function, antioxidant effect, and particularly excellent in skin aging-improving effect. However, the compositions using natural extracts extracted by conventional methods are not effective in whitening, wrinkling, and antioxidation as desired, and are difficult to maintain and control the activity of these extracts.
이에, 본 발명자들은 피부 상태 개선 효과를 제공할 수 있는 물질을 찾고자 연구한 결과, 한방 가공 기술인 포제를 활용하여 가공된 인삼 열매 추출물을 함유하는 조성물이 항노화, 보습, 미백 등의 피부 상태 개선 효과가 있음을 확인하고 본 발명을 완성하였다.Accordingly, the present inventors have searched for a substance capable of improving the skin condition and found that the composition containing the processed ginseng fruit extract by utilizing the herbicide processing technology as a herbal processing technology is effective for improving the skin condition such as anti-aging, moisturizing, And completed the present invention.
따라서, 본 발명의 목적은 포제를 활용한 인삼 열매 추출물을 제조하고 상기 추출물을 유효성분으로 함유함으로써 항노화, 보습, 미백 등의 피부 상태 개선 효과가 우수하면서 피부에 안전한 천연물을 함유한 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a composition containing natural products safe for skin, which is excellent in the skin condition improving effect such as anti-aging, moisturizing, whitening, etc., by preparing a ginseng fruit extract using fungicide and containing the extract as an active ingredient .
상기한 목적을 달성하기 위하여, 본 발명은 포제를 활용한 인삼 열매 추출물을 함유하는 조성물을 제공한다.In order to attain the above object, the present invention provides a composition containing a ginseng fruit extract using a fungus.
본 발명의 조성물은 포제를 활용한 인삼 열매 추출물을 함유함으로써 엘라스타아제 및 콜라게나아제의 발현을 억제시키는 효능이 우수하여 항노화 및 탄력 향상 효과가 우수하며 피부 노화를 억제하고 피부 수분 보유력을 증가시키며, 또한 피부 미백에 우수한 효능이 있어 피부에 안전하면서도 전반적인 피부 상태를 개선시키는 효과를 제공할 수 있다.The composition of the present invention is excellent in the effect of inhibiting the expression of elastase and collagenase by containing the extract of fruit extract using Fojer, so that it has excellent anti-aging and elasticity improving effect. It suppresses skin aging and increases skin moisture retention And has an excellent effect on skin whitening, thereby providing an effect of improving the overall skin condition while being safe for the skin.
본 발명의 조성물은 포제를 활용한 인삼 열매 추출물을 함유하며, 화장료 조성물 또는 식품 조성물로서 제공될 수 있다.The composition of the present invention contains a ginseng fruit extract using a feces, and can be provided as a cosmetic composition or a food composition.
또한, 본 발명의 조성물은 항노화, 보습, 미백 등의 효과를 제공한다.In addition, the composition of the present invention provides effects such as anti-aging, moisturizing, whitening and the like.
이하 본 발명에 대하여 보다 구체적으로 살펴본다.Hereinafter, the present invention will be described in more detail.
인삼(Panax ginseng C.A. Meyer)은 오가피과 인삼 속에 속하는 식물로서 한국, 중국 및 일본 등지에서 2,000여년 전부터 사용되어 온 생약이며, 경험적으로 질병을 예방하고 수명을 연장시킬 목적으로 사용되어 왔다. 지금까지 알려진 인삼의 효능 및 효과는 중추신경계에 대한 작용, 항발암 작용, 항암활성, 면역기능 조절작용, 항당뇨 작용, 간기능 항진효능, 심혈관 장해개선, 항동맥경화 작용, 혈압조절 작용, 갱년기 장애 개선, 골다공증에 미치는 효과, 항스트레스 및 항피로 작용, 항산화 활성 및 노화억제 효능 등이 있다(최신고려인삼 '성분 및 효능편', 한국인삼연초연구원, 56-112, 1996).Ginseng (Panax ginseng C.A. Meyer) is a herb that belongs to the genus Ogawa and Ginseng. It has been used in Korea, China and Japan for over 2,000 years and has been used empirically to prevent disease and prolong the life span. The efficacy and effect of ginseng which has been known so far can be determined by the action of the central nervous system, the anticarcinogenic action, the anticancer activity, the immune function regulating action, the anti-diabetic action, the hyperfunction of liver function, the improvement of cardiovascular disorder, (Korean Ginseng & Tobacco Research Institute, 56-112, 1996). In addition, it has been reported that the antioxidant activity and antioxidant activity of osteoporosis are improved.
인삼의 대표적 생리활성 성분인 진세노사이드(Ginsenoside)는 인삼의 지상 및 지하부에 고르게 분포되어 있으며, 특히 인삼 근(뿌리), 인삼엽 및 인삼 열매 등 부위에 따라 진세노사이드 함량뿐만 아니라 조성도 다른 것으로 알려져 있다(Attele AS et al, Biochem Pharmacol, 58; 1685-1693, 1999). Ginsenoside, which is a representative physiologically active ingredient of ginseng, is distributed evenly on the ground and underground of ginseng. Especially, ginsenoside (root), ginseng leaf and ginseng berries have not only ginsenoside content but also composition (Attele AS et al, Biochem Pharmacol, 58: 1685-1693, 1999).
한편, 본 발명에서 사용되는 인삼 열매의 추출방법은 하기와 같다.Meanwhile, the method for extracting ginseng fruit used in the present invention is as follows.
(1) 포제 가공 단계. (1) Foam processing step.
인삼 열매를 삶거나, 찌거나, 불에 볶거나, 불에 굽거나 달구는 방법으로 포제를 행하며, 또는 상기 방법들을 혼합하여 포제를 행할 수도 있다. 삶는 경우에는 100-180℃에서 0.1-1시간, 찌는 경우에는 150-200℃에서 1-48시간, 볶는 경우 100-300℃에서 0.1-1시간, 굽는 경우 180-300℃에서 0.5-5시간 등의 조건에서 가공할 수 있다. The ginseng fruit may be boiled, steamed, roasted, roasted or boiled, or the roots may be mixed with the roasted ginseng. In case of boiling, 0.1-1 hour at 100-180 ℃, 1 - 48 hours at 150-200 ℃ for steaming, 0.1-1 hour at 100-300 ℃ for roasting, 0.5 - 5 hours at 180-300 ℃ for roasting . ≪ / RTI >
(2) 추출물을 수득 단계. (2) obtaining an extract.
물 또는 유기용매를 이용하여 상기 (1) 단계를 거친 인삼 열매의 포제 추출물을 수득한다. 유기용매는 에탄올, 메탄올, 부탄올, 에테르, 에틸아세테이트 및 클로로포름으로 이루어진 군에서 선택된 하나 이상일 수 있으며, 또는 이들 유기용매와 물과의 혼합용매를 사용할 수 있다. 바람직하게는 80% 에탄올을 사용할 수 있다. The feces extract of the ginseng fruit obtained by the above step (1) is obtained by using water or an organic solvent. The organic solvent may be at least one selected from the group consisting of ethanol, methanol, butanol, ether, ethyl acetate and chloroform, or a mixed solvent of these organic solvents and water may be used. Preferably, 80% ethanol is used.
본 발명의 화장료 조성물은 상기의 방법으로 추출된 인삼 열매 포제 추출물을 유효성분으로 하여 조성물 총 중량에 대하여 0.001-30.0 중량%의 양으로 함유한다.The cosmetic composition of the present invention contains, as an active ingredient, ginseng fruit extract obtained by the above method in an amount of 0.001-30.0% by weight based on the total weight of the composition.
본 발명에 의한 조성물은 화장품용 조성물 또는 식품용 조성물로서 제조될 수 있으며, 본 발명에 의한 조성물은 경피 조성물 또는 경구 조성물로서 제조될 수 있다.The composition according to the present invention can be manufactured as a cosmetic composition or a food composition, and the composition according to the present invention can be produced as a transdermal composition or an oral composition.
구체적으로 본 발명의 화장료 조성물은 그 제형에 있어서 특별히 한정되는 바가 없으며, 예를 들면 유연화장수, 영양화장수, 유액, 마사지크림, 영양크림, 팩, 패치, 젤, 스틱, 고 타입 또는 피부 점착 타입, 분무제 화장료의 제형을 갖는 화장료 조성물일 수 있다. 예를 들면 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 파우더, 보디로션, 보디크림, 보디오일, 보디에센스 등의 화장료 제형을 가질 수 있으며 또한 로션, 연고, 겔, 크림, 패취 또는 분무제와 같은 경피 투과형 제형을 갖는 화장료 조성물 일 수 있다Specifically, the cosmetic composition of the present invention is not particularly limited in its formulation. For example, the cosmetic composition of the present invention can be used as a cosmetic composition for a cosmetic composition, such as a softening agent, a nutritional lotion, a milky lotion, a massage cream, And may be a cosmetic composition having a formulation of a spray cosmetic. For example, softening longevity, convergent lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, body oil, body essence , And may also be a cosmetic composition having transdermal delivery formulations such as lotions, ointments, gels, creams, patches or sprays
또한, 본 발명의 경구 투여용 제형으로는 예를 들면, 정제, 환제, 경질 및 연질 캅셀제, 액제, 현탁제, 유화제, 시럽제, 과립제 등이 있는데, 이들 제형은 유효성분 이외에 희석제(예: 락토즈, 덱스트로즈, 수크로즈, 만니톨, 솔비톨, 셀룰로즈 및 글리신), 활택제(예: 실리카, 탈크, 스테아르산 및 그의 마그네슘 또는 칼슘염 및 폴리에틸렌 글리콜)를 함유하고 있다. 정제는 또한 마그네슘 알루미늄 실리케이트, 전분 페이스트, 젤라틴, 트라가칸스, 메틸셀룰로즈, 나트륨 카복시메틸셀룰로즈 및 폴리비닐피롤리딘과 같은 결합제를 함유할 수 있으며, 경우에 따라 전분, 한천, 알긴산 또는 그의 나트륨 염과 같은 붕해제, 흡수제, 착색제, 향미제, 및 감미제 등의 약제학적 첨가제를 함유할 수 있다. 정제는 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다. 또한, 비경구 투여용 제형으로는, 피부 외용제, 주사제 등을 포함하고, 피부 외용제로는 연고제가 바람직하며, 주사제 제형으로 등장성 수용액 또는 현탁액일 수 있다.Examples of the formulations for oral administration of the present invention include tablets, pills, hard and soft capsules, liquids, suspensions, emulsions, syrups, granules, etc. These formulations may contain, in addition to the active ingredient, , Dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (such as silica, talc, stearic acid and its magnesium or calcium salts, and polyethylene glycols). Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally mixed with starch, agar, alginic acid or its sodium salt Such as disintegrants, absorbents, coloring agents, flavoring agents, and sweetening agents. Tablets can be prepared by conventional mixing, granulating or coating methods. The external preparation for skin includes an external preparation for skin and an injection, and the external preparation for skin is preferably an ointment, and may be an isotonic aqueous solution or suspension in the form of injection.
또한, 본 발명을 식품 조성물로 제형화할 경우 육류, 소시지, 빵, 초코렛, 캔디류, 스넥류, 과자류, 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 식품을 모두 포함하고 이에 한정되지는 않는다.In addition, when the present invention is formulated into a food composition, dairy products such as meat, sausage, bread, chocolates, candies, snacks, confectioneries, noodles, gums and ice cream, various soups, drinks, tea, drinks, And the like, and includes, but is not limited to, food in a conventional sense.
또한, 각각의 제형에 있어서 상기한 필수성분 이외에 다른 성분들은 기타 제형의 종류 또는 사용목적 등에 따라 당업자가 어려움 없이 적합하게 선정하여 배합할 수 있다.In addition, in the respective formulations, components other than the above-mentioned essential ingredients can be appropriately selected and blended by those skilled in the art according to the kind of the other formulations or the purpose of use.
본 발명에 의한 조성물은 항노화 효능이 우수하여 주름 개선 및 예방의 효과를 제공하며, 피부 보습력을 증진시킨다. 또한 피부 미백 효과도 제공하여 본 발명에 의한 조성물은 피부 상태를 전반적으로 개선시킬 수 있다.The composition according to the present invention has an excellent anti-aging effect, thereby providing an effect of preventing and preventing wrinkles and enhancing skin moisturizing power. Also provided is a skin whitening effect, the composition according to the present invention can improve overall skin condition.
이하, 하기 실시예에 의하여 본 발명을 더욱 상세하게 설명하고자 한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들만으로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are intended to illustrate the present invention, but the scope of the present invention is not limited thereto.
[비교예 1] 인삼 열매 생품의 제조[Comparative Example 1] Production of ginseng fruit product
건조한 인삼 열매 1kg에 80% 에탄올 수용액 5ℓ을 넣고, 3회 환류 추출한 다음, 15℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분리된 여액을 감압 농축하여 인삼 열매 추출물을 얻었다.To 1 kg of dried ginseng fruit, 5 L of 80% ethanol aqueous solution was added, and the mixture was refluxed three times and then immersed at 15 DEG C for 1 day. Thereafter, the residue and the filtrate were separated by filtration through a filter cloth and centrifugation, and the separated filtrate was concentrated under reduced pressure to obtain a ginseng fruit extract.
[실시예 1] 인삼 열매 주초(酒炒)의 제조[Example 1] Preparation of ginseng fruit jujube
깨끗한 인삼 열매 1kg을 일정량의 황주(10~30%)를 골고루 뿌려 술이 모두 흡수될 정도로 축축해지도록 담가 두고 이것을 초제 용기에 넣어 100~180℃에서 15분~30분 동안 볶았다. 초건(炒乾)한 인삼 열매를 꺼내서 식힌 후 80% 에탄올 수용액 5ℓ를 넣고, 3회 환류 추출한 다음, 15℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분리된 여액을 감압 농축하여 인삼 열매 주초 추출물을 얻었다.1kg of clean ginseng fruit was evenly sprinkled with a certain amount of yellow liquor (10 ~ 30%) and soaked so as to become damp enough to absorb all of the liquor, and this was put in a suppository container and fried at 100 to 180 ° C for 15 to 30 minutes. The ginseng fruits were taken out and cooled, and then 5 liters of 80% ethanol aqueous solution was added, refluxed three times, and then immersed at 15 ° C for 1 day. Thereafter, the residue and filtrate were separated by filtration and centrifugation through a filter cloth, and the separated filtrate was concentrated under reduced pressure to obtain a ginseng fruit jujuba extract.
[실시예 2] 인삼 열매 초자(醋炙)의 제조[Example 2] Manufacture of ginseng fruit gruel
건조한 인삼 열매 1kg에 식초 150~300g을 약재에 충분히 흡수 시킨 후 100~160℃에서 10분~1시간 동안 볶은 후 그늘에 말렸다. 이것에 80% 에탄올 수용액 5ℓ를 넣고, 3회 환류 추출한 다음, 15℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분리된 여액을 감압 농축하여 인삼 열매 초자 추출물을 얻었다.1kg of dried ginseng fruit, 150 ~ 300g of vinegar was sufficiently absorbed into the medicinal material and roasted at 100 ~ 160 ℃ for 10 minutes ~ 1 hour and then dried in the shade. To this was added 5 liters of an 80% aqueous ethanol solution, refluxed three times, and then immersed at 15 DEG C for 1 day. Thereafter, the residue and the filtrate were separated by filtration through a filter cloth and centrifugation, and the separated filtrate was concentrated under reduced pressure to obtain a ginseng fruit root extract.
[실시예 3] 인삼 열매 초탄(炒炭)의 제조[Example 3] Production of ginseng fruit chrysotile
건조한 인삼 열매 1kg을 230~300℃에서 인삼 열매의 외부를 탄화시켜 흑색이 되면 가열을 중지하고 상온에서 식혀 이것에 80% 에탄올 수용액 5ℓ를 넣은 후, 3회 환류 추출한 다음, 15℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분리된 여액을 감압 농축하여 인삼 열매 초탄 추출물을 얻었다.1 kg of dried ginseng fruit is carbonized outside the ginseng at 230 ~ 300 ℃. When it becomes black, heating is stopped. After cooling at room temperature, 5 liters of 80% ethanol aqueous solution is added and the mixture is refluxed for 3 times. . Thereafter, the residue and filtrate were separated by filtration through a filter cloth and centrifugation, and the separated filtrate was concentrated under reduced pressure to obtain ginseng fruit chrysanthemum extract.
[실시예 4] 인삼 열매 밀자(蜜炙)의 제조[Example 4] Production of ginseng fruit millet
건조한 인삼 열매 1kg에 꿀 200~300g을 약재에 충분히 흡수시킨 다음 100~160℃에서 10분~1시간 동안 볶은 후 그늘에 말렸다. 이것에 80% 에탄올 수용액 5ℓ를 넣고, 3회 환류 추출한 다음, 15℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분리된 여액을 감압 농축하여 인삼 열매 밀자 추출물을 얻었다.200-300g of honey was absorbed into 1kg of dried ginseng fruit sufficiently and then roasted at 100 ~ 160 ℃ for 10 minutes ~ 1 hour and then dried in the shade. To this was added 5 liters of an 80% aqueous ethanol solution, refluxed three times, and then immersed at 15 DEG C for 1 day. Thereafter, the residue and the filtrate were separated by filtration through a filter cloth and centrifugation, and the separated filtrate was concentrated under reduced pressure to obtain a ginseng fruit mill extract.
[실시예 5] 인삼 열매 염자(鹽炙)의 제조[Example 5] Preparation of ginseng fruit salt
건조한 인삼 열매 1kg을 소금물(2~3%)에 잘 혼합 시킨 후 밀폐시켜 완전히 흡수 되도록 방치하고, 소금물이 완전히 흡수된 인삼 열매를 100~180℃에서 초제 용기에 넣은 다음 10분~1시간 동안 볶은 후 그늘에 말렸다. 이것에 80% 에탄올 수용액 5ℓ를 넣고, 3회 환류 추출한 다음, 15℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분리된 여액을 감압 농축하여 인삼 열매 염자 추출물을 얻었다.1kg of dried ginseng fruit is mixed well with salt water (2 ~ 3%), sealed and completely absorbed. The ginseng fruit which has been completely absorbed with salt water is put into a supergiant container at 100 ~ 180 ℃ and roasted for 10 minutes ~ 1 hour Then I dried it in the shade. To this was added 5 liters of an 80% aqueous ethanol solution, refluxed three times, and then immersed at 15 DEG C for 1 day. Thereafter, the residue and filtrate were separated by filtration through a filter cloth and centrifugation, and the separated filtrate was concentrated under reduced pressure to obtain a ginseng fruit seed extract.
[실시예 6] 인삼 열매 강자(薑炙)의 제조[Example 6] Manufacture of ginseng fruit juice
신선한 생강을 마쇄한 후 두배의 물을 넣어 혼합하여 압착한뒤 즙을 짜내었다. 이를 2~3회 반복하여 수행하여 생강즙을 준비하고, 인삼 열매 1kg에 생강즙 100~150g을 뿌려 골고루 축인 후 생강즙이 스며들면 100~180℃에서 용기에 넣고 10분~1시간 동안 볶은 후 그늘에 말렸다. 이것에 80% 에탄올 수용액 5ℓ를 넣고, 3회 환류 추출한 다음, 15℃에서 1일간 침적시켰다. 그 후, 여과포 여과와 원심분리를 통해 잔사와 여액을 분리하고, 분리된 여액을 감압 농축하여 인삼 열매 강자 추출물을 얻었다.Fresh ginger was crushed, and then double water was added to the mixture. The mixture was squeezed and squeezed. The ginger juice was prepared by repeating this 2-3 times. The ginger juice was sprayed with 100-150 g of ginger juice in 1 kg of the ginger juice, and then the ginger juice was poured into the container at 100-180 ° C., roasted for 10 minutes to 1 hour, and then dried in the shade . To this was added 5 liters of an 80% aqueous ethanol solution, refluxed three times, and then immersed at 15 DEG C for 1 day. Thereafter, the residue and filtrate were separated by filtration through a filter cloth and centrifugation, and the separated filtrate was concentrated under reduced pressure to obtain a ginseng fruit extract.
[시험예 1] 엘라스타아제 발현 억제 효능 측정[Test Example 1] Measurement of inhibitory effect on elastase expression
상기 비교예 1과 실시예 1~6으로부터 얻은 인삼 열매 및 인삼 열매 포제 추출물의 엘라스타아제 생성 저해능을 토코페롤 및 EGCG와 비교하여 측정하였다.The inhibitory effect of the ginseng fruit and ginseng fruit extract obtained from Comparative Example 1 and Examples 1 to 6 on elastase production was measured in comparison with tocopherol and EGCG.
2.5%의 우태아 혈청이 함유된 DMEM(Dulbecco's Modified Eagle's Media) 배지가 들어있는 96공 평판배양기(96-well microtiter plate)에 인간의 섬유아세포를 5,000 세포/공(well)이 되도록 넣고, 90% 정도 자랄 때까지 배양하였다. 그 후 무혈청 배지로 24시간 배양하고, 무혈청 배지에 녹여진 상기 비교예 1과 실시예 1~6의 인삼 열매 및 인삼 열매 포제 추출물, 토코페롤 및 EGCG를 10-4 몰농도로 24시간 동안 처리한 다음, 세포배양액을 채취하였다. Human fibroblasts were plated at 5,000 cells / well in a 96-well microtiter plate containing DMEM containing 2.5% fetal bovine serum (Dulbecco's Modified Eagle's Media) Lt; / RTI > until growth. Thereafter, the cells were cultured in serum-free medium for 24 hours, treated with ginseng fruit and ginseng fruit extract, tocopherol and EGCG of Comparative Example 1 and Examples 1 to 6 dissolved in serum-free medium for 24 hours at a concentration of 10 -4 mol Then, the cell culture fluid was collected.
상업적으로 이용가능한 엘라스타아제 측정기구(미국 아머샴파마샤 사)를 이용하여 채취한 세포배양액의 엘라스타아제 생성 정도를 측정하였다. 먼저 1차 엘라스타아제 항체가 균일하게 도포된 96-공 평판(96-well plate)에 채취된 세포 배양액을 넣고 3시간 동안 항원-항체 반응을 항온조에서 실시하였다. 3시간 후 발색단이 결합된 2차 엘라스틴 항체를 96-공 평판(96-well plate)에 넣고 다시 15분간 반응시켰다. 15분 후 발색유발물질을 넣어 실온에서 15분간 발색을 유발시키고, 다시 1M 황산을 넣어 발색반응을 중지시키면 반응액의 색깔은 노란색을 띠게 되며 반응 진행의 정도에 따라 노란색의 정도가 다르게 나타났다.The degree of production of elastase in the cell culture was measured using a commercially available elastase measuring device (Amersham Pharmacia, USA). First, the cell culture medium collected on a 96-well plate uniformly coated with primary ELASA antibody was added and the antigen-antibody reaction was performed in a thermostatic chamber for 3 hours. After 3 hours, the secondary elastin antibody bound to the chromophore was placed in a 96-well plate and reacted again for 15 minutes. After 15 minutes, the color development inducing substance was added to induce color development at room temperature for 15 minutes, and 1M sulfuric acid was added again to stop the color development reaction. The color of the reaction solution became yellow, and the degree of yellow was different according to the progress of the reaction.
노란색을 띠는 96-공 평판(96-well plate)의 흡광도를 흡광계를 이용하여 405nm에서 측정하고, 하기 수학식 1에 의해 엘라스타아제의 발현정도를 계산하였으며, 그 결과는 하기 표 1에 나타내었다. 이때 조성물을 처리하지 않은 군에서 채취된 세포배양액의 반응 흡광도를 대조군으로 하였다. The absorbance of a yellow 96-well plate was measured at 405 nm using a spectrophotometer and the degree of expression of elastase was calculated by the following equation (1) Respectively. At this time, the reaction absorbance of the cell culture fluid collected from the non-treated group was used as a control.
상기 표 1에 나타낸 바와 같이, 시험관내(in vitro)에서 실시예 1~6의 엘라스타아제 발현 정도가 인삼 열매 추출물 비교예 1과 비교하여 낮은 것을 통해 본 발명에 의한 인삼 열매 포제 추출물의 엘라스타아제 발현 저해 효과가 더 좋음을 확인할 수 있다. 또한, 엘라스타아제 발현 저해제로 알려져 있는 토코페롤 및 EGCG와 비교하여서도 본 발명에 의한 인삼 열매 포제 추출물의 엘라스타아제 발현 저해 효과가 토코페롤보다는 우수하고, EGCG와는 비슷한 수준임을 알 수 있다.As shown in Table 1, the degree of expression of elastase in Examples 1 to 6 in vitro was lower than that of Comparative Example 1 of the ginseng fruit extract, Suggesting that the effect of inhibiting the expression of the enzyme is better. In addition, compared with tocopherol and EGCG, which are known as inhibitors of elastase expression, the inhibitory effect on elastase expression of the extract of ginseng root according to the present invention is superior to tocopherol and is similar to that of EGCG.
[시험예 2] 콜라게나아제(MMP-1) 저해능[Test Example 2] Collagenase (MMP-1)
상기 비교예 1과 실시예 1~6으로부터 얻은 인삼 열매 및 인삼 열매 포제 추출물의 콜라게나아제 생성 저해능을 레티노익산과 비교하여 측정하였다.The inhibitory effect of the extracts of ginseng and ginseng extract prepared from Comparative Example 1 and Examples 1 to 6 on collagenase production was compared with that of retinoic acid.
2.5%의 우태아 혈청이 함유된 DMEM(Dulbecco's Modified Eagle's Media) 배지가 들어있는 96공 평판배양기(96-well microtiter plate)에 인간의 섬유아세포를 5,000 세포/공(well)이 되도록 넣고, 70~80% 정도 자랄 때까지 CO2 5%, 37℃ 배양기(incubator)에서 배양하였다. 그 후 비교예 1과 실시예 1~6의 인삼 열매 및 인삼 열매 포제 추출물을 10-4 몰농도로 24시간 동안 처리한 다음, 세포배양액을 채취하였다. Human fibroblasts were plated at 5,000 cells / well in a 96-well microtiter plate containing 2.5% fetal calf serum-containing DMEM (Dulbecco's Modified Eagle's Media) And incubated at 37 ° C in an incubator with CO 2 of 5% until it grew to about 80%. Then, the ginseng fruit and ginseng fruit extract of Comparative Example 1 and Examples 1 to 6 were treated for 24 hours at a concentration of 10 -4 mol, and the cell culture solution was collected.
상업적으로 이용가능한 콜라게나아제 측정기구(미국 아머샴파마샤 사, Catalog #: RPN 2610)를 이용하여 채취한 세포배양액의 콜라게나아제 생성 정도를 측정하였다. 먼저 1차 콜라게나아제 항체가 균일하게 도포된 96-공 평판(96-well plate)에 채취한 세포 배양액을 넣고 3시간 동안 항원-항체 반응을 항온조에서 실시하였다. 3시간 후 발색단이 결합된 2차 콜라겐 항체를 96-공 평판(96-well plate)에 넣고 다시 15분간 반응시켰다. 15분 후 발색유발물질(3,3',5,5'-tetramethylbenzidine, sigma)을 넣어 실온에서 15분간 발색을 유발시키고, 다시 1M 황산을 넣어 발색반응을 중지시키면 반응액의 색깔은 노란색을 띠게 되며 반응 진행의 정도에 따라 노란색의 정도가 다르게 나타났다. The degree of collagenase production in the cell culture was measured using a commercially available collagenase assay device (Amersham Pharmacia, USA, Catalog #: RPN 2610). First, the cell culture solution collected on a 96-well plate uniformly coated with primary collagenase antibody was added and the antigen-antibody reaction was performed in a thermostatic chamber for 3 hours. After 3 hours, the second collagen antibody bound to the chromophore was placed in a 96-well plate and reacted for another 15 minutes. After 15 minutes, the color development substance (3,3 ', 5,5'-tetramethylbenzidine, sigma) was added and color development was induced at room temperature for 15 minutes. When 1 M sulfuric acid was added to stop the color development reaction, the color of the reaction solution became yellow And the degree of yellowing was different according to the progress of the reaction.
노란색을 띠는 96-공 평판(96-well plate)의 흡광도를 흡광계를 이용하여 405nm에서 측정하고, 하기 수학식 2에 의해 콜라게나아제의 합성 정도를 계산하였으며, 그 결과는 하기 표 2에 나타내었다. 이때 조성물을 처리하지 않은 군에서 채취한 세포 배양액의 반응 흡광도를 대조군으로 하였다. The absorbance of a yellow 96-well plate was measured at 405 nm using a spectrophotometer and the degree of synthesis of collagenase was calculated by the following equation (2) Respectively. At this time, the reaction absorbance of the cell culture fluid collected from the non-treated group was used as a control.
상기 표 2에 나타낸 바와 같이, 시험관내(in vitro)에서 실시예 1~6의 콜라게나아제 발현 정도가 인삼 열매 추출물 비교예 1과 비교하여 낮은 것을 통해 본 발명에 의한 인삼 열매 포제 추출물의 콜라게나아제 발현 저해 효과가 더 좋음을 확인할 수 있다. 또한, 콜라게나아제 발현 저해제로 알려져 있는 레티노익산과 비교하여서도 본 발명에 의한 인삼 열매 포제 추출물의 콜라게나아제 발현 저해 효과가 레티노익산과 비슷한 수준임을 알 수 있다.As shown in Table 2, the degree of collagenase expression of Examples 1 to 6 in vitro was lower than that of Comparative Example 1 of the ginseng fruit extract, and the collagenase of the ginseng fruit extract of the present invention Suggesting that the effect of inhibiting the expression of the enzyme is better. In addition, in comparison with retinoic acid, which is known as a collagenase expression inhibitor, the inhibitory effect of collagenase on the expression of collagenase in the extract of ginseng fruit according to the present invention is similar to that of retinoic acid.
이와 같은 결과를 통하여, 본 발명에 의한 인삼 열매 포제 추출물은 기질 메탈로 프로테아제(MMP-1)를 저해시키는 효과를 가짐을 확인할 수 있다.From these results, it can be confirmed that the extract of ginseng root according to the present invention has an effect of inhibiting the substrate metalloprotease (MMP-1).
[시험예 3] 피부 탄력 향상 효능 확인[Test Example 3] Confirmation of improving skin elasticity
피부 탄력 향상 효능 확인을 위하여 상기 비교예 1 및 실시예 1~6에서 얻은 인삼 열매 및 인삼 열매 포제 추출물을 활용하여 하기 표 3의 조성으로 비교제형예 1 및 제형예 1~6의 화장수를 제조하고 인삼 열매 또는 인삼 열매 포제 추출물을 함유하지 않는 화장수를 대조군으로 제조하였다.To confirm the skin elasticity improving effect, the lotion of Comparative Example 1 and Formulations 1 to 6 was prepared using the ginseng fruit and ginseng fruit extract obtained in Comparative Example 1 and Examples 1 to 6, with the composition shown in Table 3 below Ginseng fruit or ginseng fruit lotion containing no extracts was prepared as a control.
상기 대조군, 비교제형예 1 및 제형예 1~6 화장수의 피부 탄력 향상 효과를 비교하기 위하여, 30~40대 여성 160명을 대상으로 20명을 1개군으로 하여 8개군으로 나누어 측정하였다. 실험 방법은 다음과 같다.In order to compare skin elasticity improvement effects of the control group, Comparative Formulation Example 1 and Formulation Examples 1 to 6, 160 individuals of 30 to 40 years old women were divided into eight groups of 20 persons as one group. The experimental method is as follows.
각 조에 대조군, 비교제형예 1 또는 제형예 1~6의 화장수를 각각 나누어 주고 매일 1회 12주간 눈가에 일정량을 도포하게 하였다. 이때, 피검자의 눈가의 왼쪽에는 상기 대조군의 화장수를, 오른쪽에는 비교제형예 1 또는 제형예 1~6의 화장수를 도포하게 하였다. 12주 뒤 피부탄력을 측정할 수 있는 큐토미터(cutometer; SEM474, Courage+Khazaka electronic GmbH. Germany)를 이용하여 각 그룹의 피부 탄력을 측정하고 그 평균을 구하였으며, 그 결과는 하기 표 4에 나타내었다.To each group, control lotions, Comparative Formulation Example 1, or Formulation Examples 1 to 6 were applied to each eye, and a predetermined amount of the lotion was applied once a day for 12 weeks. At this time, the lotion of the control group was applied to the left side of the eye of the subject, and the lotion of Comparative Formulation Example 1 or Formulations 1 to 6 was applied to the right side. After 12 weeks, skin elasticity of each group was measured and averaged using a cutometer (SEM474, Courage + Khazaka electronic GmbH, Germany) capable of measuring skin elasticity, and the results are shown in Table 4 .
상기 표 4의 결과를 보면, 본 발명에 의한 인삼 열매 포제 추출물을 함유한 제형예 1~6의 화장수를 사용한 경우에 인삼 열매 추출물을 함유하고 있지 않은 대조군과 비교하여 피부 탄력 향상도가 3배 정도 높게 나타남을 확인할 수 있으며, 인삼 열매의 단순 추출물을 함유한 비교제형예 1의 화장수를 사용한 경우와 비교하여서도 피부 탄력 향상도가 월등히 우수함을 알 수 있다.The results of Table 4 show that when the lotion formulations of Formulation Examples 1 to 6 containing the extract of ginseng root extract according to the present invention were used, the elasticity of the skin was improved to about three times as compared with the control group not containing the ginseng fruit extract And the improvement in skin elasticity is remarkably superior to that in the case of using the cosmetic lotion of Comparative Formulation Example 1 containing a simple extract of ginseng fruit.
따라서, 본 발명의 인삼 열매 포제 추출물을 함유하는 화장료 조성물은 피부 탄력 향상에 매우 효과적임을 확인할 수 있다.Accordingly, it can be confirmed that the cosmetic composition containing the ginseng fruit extract of the present invention is very effective for improving skin elasticity.
[시험예 4] 쥐의 색소세포를 이용한 멜라닌 생성 억제효과 측정[Test Example 4] Measurement of inhibitory effect on melanin formation using mouse pigment cells
C57BL/6 마우스 유래의 쥐의 색소세포(Mel-Ab cell)(Dooley, T.P. et al, Skin pharmacol, 7, pp 188-200)를 DMEM에 10% 우태반 혈청, 100nM 12-O-테트라데카노일포르볼(tetradecanoylphorbol)-13-아세테이트, 1nM 콜레라 독소(cholera toxin)를 첨가한 배지에서 37℃, 5% CO2의 조건에서 배양하였다. 배양된 Mel-Ab 세포를 0.25% 트립신-EDTA로 떼어내고, 24-웰 플레이트에 105 세포/웰(cells/well)의 농도로 세포를 배양한 다음, 이틀째부터 3일 연속으로 각 시험물질을 가하여 배양하였다. 시험물질로는 하이드로퀴논과 상기 실시예 1~6의 인삼 열매 포제 추출물을 10ppm의 농도로 하여 사용하였다. 이때, 상기 하이드로퀴논은 양성대조군으로 사용하였다. 그 다음 배양액을 제거하고, PBS로 세척한 후, 1N 수산화나트륨으로 세포를 녹여 400nm에서 흡광도를 측정한 다음, 하기 수학식 3에 따라 멜라닌 생성 억제율을 계산하여 그 결과를 표 5에 나타내었다(Dooley의 방법).The cells were cultured in DMEM supplemented with 10% fetal bovine serum, 100 nM 12-O-Tetradecanoyl (10 nM) Acetate, and 1 nM cholera toxin at 37 ° C in the presence of 5% CO 2 . The cultured Mel-Ab cells were removed with 0.25% trypsin-EDTA, and the cells were cultured at a concentration of 10 5 cells / well (cells / well) in a 24-well plate. And cultured. Hydroquinone and the ginseng fruit extract of Examples 1 to 6 were used as test substances at a concentration of 10 ppm. At this time, the hydroquinone was used as a positive control. Then, the culture solution was removed, washed with PBS, and the cells were dissolved with 1 N sodium hydroxide, and the absorbance at 400 nm was measured. The rate of inhibition of melanin production was calculated according to the following equation (3) Method).
상기 표 5에 나타낸 바와 같이, 본 발명의 인삼 열매 포제 추출물이 공지된 미백 물질인 하이드로 퀴논과 유사한 정도의 멜라닌 생성 억제율을 보이는 것을 확인할 수 있다.As shown in Table 5, it can be confirmed that the extract of ginseng root extract of the present invention shows a degree of inhibition of melanin formation similar to that of hydroquinone, which is a known whitening substance.
[시험예 5] PPARs 활성화 확인[Test Example 5] Confirmation of activation of PPARs
인체 각질형성 세포주(human keratinocyte)인 HaCaT을 10% 우태아 혈청을 포함하는 DMEM 배지에 계대 배양하고 페놀 레드의 에스트로겐에 의한 효과를 제거하기 위해 페놀 레드-프리(phenol red-free) 배지를 사용하였다. 플라스미드는 일반적인 배양 조건에서도 발현되는 유니버설(universal) 프로모터 뒤에 PPARα, PPARβ/δ, PPARγ 유전자를 지닌 플라스미드와 리간드 결합형의 PPARs가 결합하여 활성화되는 PPARs 반응 요소(PPARs Response Element, “PPRE”)를 프로모터로 가지고 뒤에 리포터로써 역할을 하는 반디불(firefly) 루시퍼라제(luciferase) 유전자를 지닌 것, 그리고 참조(reference)로 사용될 유니버설 프로모터에 β-갈락토시다제(β-galactosidase) 유전자가 결합된 플라스미드가 사용되었다(Proc. Natl. Acad. Sci. USA, 91 (1994) 7355-7359).HaCaT, a human keratinocyte, was subcultured in a DMEM medium containing 10% fetal bovine serum and phenol red-free medium was used to eliminate the effect of estrogen on phenol red . The plasmid is a promoter of the PPARs response element (PPRE), which is activated by binding of a plasmid having PPAR?, PPAR? /?, PPAR? Gene and ligand-binding PPARs after a universal promoter expressed under ordinary culture conditions. A plasmid in which a firefly luciferase gene is used as a reporter and a universal promoter to be used as a reference is coupled with a β-galactosidase gene (Proc. Natl. Acad. Sci. USA, 91 (1994) 7355-7359).
HaCaT 세포를 5x104의 농도로 24 웰(well)형 플레이트에 분주하고 24 시간 배양한 후, 상기 플라스미드 유전자를 일시적 트랜스펙션(transient transfection)하였다. 24 시간 배양 후 인산완충용약(PBS)으로 세척한 후 7,3',4'-트리하이드록시이소플라본과 양성대조군으로 기존에 알려진 PPARs 리간드(PPARα 리간드인 Wy-14,643, PPARγ 리간드인 트로글리타존(troglitazone, “TGZ”))를 명시된 농도로 처리하였다. 음성대조군으로는 시료들을 녹일 때 사용한 에탄올을 처리한 군을 이용하였다. 24 시간 배양 후 PBS로 세척하고 세포를 수확하여 루시퍼라제 활성을 측정하여 표 6 및 표 7에 나타내었다.HaCaT cells were plated in a 24 well plate at a concentration of 5x10 < 4 > and cultured for 24 hours. Then, the plasmid gene was transiently transfected. After incubation for 24 hours, the cells were washed with phosphate buffered saline (PBS), and 7,3 ', 4'-trihydroxyisoflavone and a positive control were added to PPARs ligand (Wy-14,643, PPARγ ligand, troglitazone , &Quot; TGZ ")) were treated at the specified concentrations. As the negative control group, the ethanol treated group used for lysing the samples was used. After culturing for 24 hours, the cells were washed with PBS, and the luciferase activity was measured by harvesting the cells. The results are shown in Table 6 and Table 7.
표 6은 연구에 사용되는 HaCaT 세포주에 PPRE 프로모터 리포터 플라즈미드와 PPARα 발현 플라즈미드를 트랜스펙션 시킨 후, 약물을 처리하고 루시퍼라제 활성을 측정한 결과이다. 표 7은 PPARγ 발현 플라즈미드와 PPRE 프로모터 리포터 플라즈미드를 동시에 트랜스펙션시킨 후 약물을 처리하고 루시퍼라제 활성을 측정한 결과이다. Table 6 shows the result of transfection of PPAR promoter reporter plasmid and PPARa expression plasmid into the HaCaT cell line used in the study, followed by treatment with the drug and measurement of luciferase activity. Table 7 shows the result of the simultaneous transfection of the PPAR gamma expression plasmid and the PPRE promoter reporter plasmid, followed by treatment of the drug and measurement of luciferase activity.
표 6 및 표 7을 보면, 본 발명에 의한 실시예 1~6을 사용한 경우 유의한 정도의 PPARα 및 PPARγ의 활성을 유도하여 높은 루시퍼라제 활성을 나타냄을 확인할 수 있다.Table 6 and Table 7 show that when Examples 1 to 6 according to the present invention are used, a significant degree of activity of PPAR? And PPAR? Is induced and exhibits high luciferase activity.
[시험예 6] 각질형성세포 분화 촉진 효과 [Test Example 6] Promoting effect of keratinocyte differentiation
상기 샘플들의 각질형성세포의 분화 촉진 효과를 알아보기 위해, 하기와 같이 각질형성세포의 분화시 생성되는 CE(Cornified Envelop)양을 흡광도를 이용하여 측정하였다. In order to examine the differentiation promoting effect of keratinocytes in the samples, the amount of corned envelope (CE) generated upon differentiation of keratinocytes was measured using absorbance.
먼저, 신생아의 표피로부터 분리해 일차 배양한 사람의 각질형성세포를 배양용 플라스크에 넣어 바닥에 부착시킨 뒤 하기 표 8의 시험물질을 배양액에 1ppm 농도로 처리한 후 세포가 바닥 면적의 70~80 % 정도 자랄 때까지 5일간 배양하였다. 이때, 저칼슘(0.03mM) 처리군과 고칼슘(1.2mM) 처리군을 각각 음성 대조군, 양성 대조군으로 하였다. 그 다음 상기 배양한 세포를 수확하여 PBS(Phophate buffered saline)로 세척한 뒤 2% SDS(sodium dodecyl sulfate)와 20mM 농도의 DTT(Dithiothreitol)를 함유한 10mM 농도의 트리스-염산 완충액(Tris-HCl, pH 7.4) 1ml를 가하여 소니케이션(sonication), 보일링(boiling), 원심분리한 후 침전물을 다시 PBS 1ml에 현탁시켜 340 nm 에서의 흡광도를 측정하였다. 이와 별도로 상기 소니케이션 후의 용액을 일부 취하여 단백질 함량을 측정하고, 세포 분화정도 평가시 기준으로 삼았다. 그 결과를 하기 표 8에 나타내었다. First, the keratinocytes of the primary culture separated from the epidermis of the newborn baby are placed in a culture flask and adhered to the bottom. After the test substance of Table 8 is treated at a concentration of 1 ppm in the culture medium, % ≪ / RTI > until growth. At this time, low calcium (0.03 mM) and high calcium (1.2 mM) treatment groups were negative control and positive control, respectively. Then, the cultured cells were harvested, washed with PBS (Phosphate buffered saline), and then suspended in 10 mM Tris-HCl buffer (Tris-HCl, pH 7.4) containing 2% SDS (sodium dodecyl sulfate) and 20 mM DTT (Dithiothreitol) pH 7.4) was added, sonication, boiling, and centrifugation. The precipitate was suspended again in 1 ml of PBS and the absorbance at 340 nm was measured. Separately, a part of the solution after the sonication was taken to measure the protein content and used as a standard in evaluating the degree of cell differentiation. The results are shown in Table 8 below.
상기 표 8에 나타낸 바와 같이, 본 발명에 의한 실시예 1~6이 유의한 정도의 각질형성세포의 분화를 촉진하는 것을 알 수 있다. As shown in Table 8, it can be seen that Examples 1 to 6 according to the present invention promote the differentiation of keratinocytes to a significant degree.
[시험예 7] 무모생쥐 피부에서의 피부 장벽기능 회복 및 피부 보습력 증가 효과 측정[Test Example 7] Measurement of effect of restoring skin barrier function and increasing skin moisturizing power in hairless mouse skin
상기 샘플들이 피부 손상으로 인해 손상된 피부 장벽기능의 회복에 미치는 효과 및 피부 보습력 증가에 미치는 효과를 측정하기 위하여, 하기와 같은 실험을 수행하였다. In order to measure the effect of the samples on the recovery of the damaged skin barrier function due to skin damage and the effect on the increase in skin moisturizing ability, the following experiment was conducted.
먼저, 출생 후 8∼10 주 경과한 무모생쥐(Charles River, Japan)의 등에 아세톤을 1일 2회씩 5일 동안 주기적으로 도포하여 실험동물 등 피부의 장벽 기능 손실을 유도한 다음 증발계(Evaporimeter)로 TEWL(Transepidermal water loss, 경피수분손실)을 측정하여 40g/m2/hr 이상의 경피수분손실을 나타내는 피부를 가진 실험동물만을 대상으로 하였다. 선택한 실험동물에 대하여 시험물질로 프로필렌 글리콜과 에탄올을 7:3의 비율로 혼합한 비히클(Vehicle)(비히클 처리군)과 실시예 1~6을 각각 1% 함유한 샘플을 피부면적 5cm2 당 200μl의 용량으로 1일 2회씩 3일 동안 연속 도포하면서 일정 시간마다 TEWL을 측정하였으며, 그 결과를 표 9에 나타내었다. First, acetone was applied to the mice (Charles River, Japan) at 8 to 10 weeks after birth periodically for 5 days twice a day to induce barrier function of the skin, such as experimental animals, and then to an evaporator TEWL (transepidermal water loss) was measured to determine the transdermal water loss of more than 40 g / m 2 / hr. A vehicle (vehicle-treated group) mixed with propylene glycol and ethanol at a ratio of 7: 3 as a test substance to the selected experimental animals and a sample containing 1% each of Examples 1 to 6 at a ratio of 200 μl per 5 cm 2 of skin area , And the TEWL was measured at a constant time while continuously applying for 3 days twice a day. The results are shown in Table 9.
또한, 코니오미터(Corneometer, 독일 Courage Khazaka 사)를 사용하여 피부 수분량을 동시에 측정하였으며, 그 결과를 표 10에 나타내었다. 이때 무처리군의 피부 수분량도 함께 측정하였다.The moisture content of the skin was measured simultaneously using a corneometer (Courage Khazaka, Germany). The results are shown in Table 10. At this time, the skin moisture of the untreated group was also measured.
표 9에 나타낸 바와 같이 상기 실시예 1~6의 처리군이 빠르게 장벽 손상이 회복되었음을 알 수 있다. 또한 표 10에 나타낸 바와 같이 피부 수분량에 있어서도 실시예 1~6의 처리군이 높게 나타남을 확인할 수 있다. As shown in Table 9, it can be seen that the treatment groups of Examples 1 to 6 recovered the barrier damage rapidly. Also, as shown in Table 10, it can be confirmed that the treatment groups of Examples 1 to 6 are high in the amount of skin moisture.
따라서, 이를 통해 상기 인삼 열매 포제 추출물을 처리한 경우 장벽 손상 회복과 더불어 피부 수분량도 증가함을 알 수 있으며, 또한 인삼 열매 포제 추출물을 사용할 경우 인삼 열매 생품의 추출물을 사용할 경우보다 그 효능이 더 우수함을 확인할 수 있다.Accordingly, it can be seen that when the ginseng fruit forage extract is treated, the skin moisture content increases as well as the barrier damage recovery. Also, when the extract of ginseng fruit extract is used, the efficacy is better than that of the extract of ginseng fruit product can confirm.
Claims (8)
상기 밀자 포제 처리한 인삼열매는 인삼열매를 꿀에 넣어 꿀을 흡수시킨 후, 100~160℃의 온도에서 10분~1시간 동안 볶은 다음, 음지에서 건조시켜 얻은 것임을 특징으로 하는, 피부 미백 개선용 화장료 조성물.A cosmetic composition for skin whitening improvement comprising, as an active ingredient, an extract of a ginseng fruit which has been subjected to forage treatment by a milling method,
The ginseng fruit treated with the wheat flour is obtained by putting the fruit of ginseng in honey and absorbing the honey, roasting it at a temperature of 100 to 160 ° C for 10 minutes to 1 hour and then drying it on a shade. Cosmetic composition.
상기 주초 포제 처리한 인삼열매는 인삼열매를 용기 중의 황주에 담근 후, 100~180℃의 온도에서 15분~30분 동안 볶아 건조시켜 얻은 것임을 특징으로 하는, 피부 항노화용 화장료 조성물.Claims 1. A cosmetic composition for anti-aging skin comprising an extract of ginseng fruit which has been subjected to forage treatment by a main-seeding process as an active ingredient,
The cosmetic composition for skin anti-aging according to any one of the above claims, characterized in that the ginseng fruit which has been subjected to forage treatment is obtained by immersing the ginseng fruit in the yellow juice of the container and roasting it for 15 to 30 minutes at a temperature of 100 to 180 ° C.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170176447A KR101924446B1 (en) | 2017-12-20 | 2017-12-20 | Composition containing ginseng berry extract using processing of herbal medicine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170176447A KR101924446B1 (en) | 2017-12-20 | 2017-12-20 | Composition containing ginseng berry extract using processing of herbal medicine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100017582A Division KR101819727B1 (en) | 2010-02-26 | 2010-02-26 | Composition containing ginseng berry extract using processing of herbal medicine |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180002079A true KR20180002079A (en) | 2018-01-05 |
KR101924446B1 KR101924446B1 (en) | 2018-12-03 |
Family
ID=61001742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170176447A KR101924446B1 (en) | 2017-12-20 | 2017-12-20 | Composition containing ginseng berry extract using processing of herbal medicine |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101924446B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11717012B2 (en) | 2020-03-31 | 2023-08-08 | Amorepacific Corporation | Composition comprising ginseng seed oil |
-
2017
- 2017-12-20 KR KR1020170176447A patent/KR101924446B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11717012B2 (en) | 2020-03-31 | 2023-08-08 | Amorepacific Corporation | Composition comprising ginseng seed oil |
Also Published As
Publication number | Publication date |
---|---|
KR101924446B1 (en) | 2018-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101819727B1 (en) | Composition containing ginseng berry extract using processing of herbal medicine | |
KR102126469B1 (en) | Cosmetic Compositions comprising extract of Dendrobium candidum flower extract | |
KR20110098122A (en) | Composition containing ginseng berry fermentation extract using bacteria | |
KR20150139688A (en) | The Extract Of The Citrus grandis Osbeck Having Skin Whitening Activity And Cosmetic Composition Containing The Same | |
KR102683145B1 (en) | Composition for preventing or improving skin aging comprising an extract of rhodiola sachalinesis fermented by bovista plumbea | |
KR101824770B1 (en) | Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract | |
KR102022622B1 (en) | Composition for improving skin conditions comprising panax ginseng sprout extract or fraction thereof and method for improving skin conditions using the same | |
KR101295368B1 (en) | Composition for skin wrinkle improvement comprising extracts of honeybush extract or its fermentation solution as an active ingredient | |
KR101026879B1 (en) | Producing method of cosmetic composition for improving skin wrinkle | |
KR102158780B1 (en) | Composition for improving skin comprising natural material extract | |
KR102236071B1 (en) | Composition for Improving Skin Trouble Using an Extract of Centella asiatica or Paeonia lactiflora Cultured with Magma Seawater | |
KR101924446B1 (en) | Composition containing ginseng berry extract using processing of herbal medicine | |
KR101480696B1 (en) | Cosmetic composition containing extracts of Adenophora triphylla var. japonica Hara, Angelica tenuissima and crude drugs | |
KR20210045529A (en) | Method for preparing fermentated ziziphus jujuba seed | |
KR102471009B1 (en) | Cosmetic composition containing Albiggia kalkora extract for skin whitening and improving wrinkles | |
KR20090097550A (en) | Cosmetic composition containing schizandrin and extracts | |
KR20080020749A (en) | Ginseng fermented by vegetable worm, the extract thereof and the use thereof | |
KR102057376B1 (en) | Composition for skin whitening comprising extract of stichopus japonicas red | |
KR102244585B1 (en) | Complex cosmetic composition for improving skin-aging | |
KR101069906B1 (en) | A composition for improving skin conditions comprising extract of Aster subulatus Michx. | |
KR102326086B1 (en) | Composition for Improving Skin Conditions Having Skin Whitening, Moisturizing, Anti-Wrinkle and Skin Barrier Property Comprising Complex Extracts of Broussonetia kazinoki as Active Ingredient | |
KR101515443B1 (en) | The functional cosmetic composition for anti-wrinkle, skin whitening and recovery of distrupted skin containing, comprising the mixture of extract of bergamot, Lonicera japonica Thunberg, Coix lachryma-jobi var. mayuen and wheat bud | |
KR102583304B1 (en) | Composition for Anti-glycation, Whitening and Skin Condition Improvement Comprising Plant Complex Extracts as Active Ingredient | |
KR101070886B1 (en) | A composition comprising pachydictyon coriaceum extract | |
KR101521579B1 (en) | Skin Whitening and Anti―oxidative Composition Containing Boesenbergia rotunda Extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
GRNT | Written decision to grant | ||
X701 | Decision to grant (after re-examination) |